Trial Profile

An Open Label Phase 1b/2 Study of Orally Administered PLX 3397 in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 20 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Jun 2020 Results of a genomic analysis using (FFPE) TGCT specimens from six clinical studies: NCT01004861, NCT02777710, NCT01217229, NCT01525602, NCT01790503 and NCT02452424 assessing CSF1 genetic alterations and rearrangements presented at the 111th Annual Meeting of the American Association for Cancer Research - II
19 Jun 2020 Status changed from active, no longer recruiting to completed.
18 Feb 2020 Planned End Date changed from 1 Oct 2019 to 1 Oct 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com